Four years after they were proposed, CMS has finalized a series of discharge planning changes that went into effect on October 29. The final rule, called Revisions to Discharge Planning Requirements [CMS-3317-F], imposes a number of new requirements—ranging from how to notify patients about their choice in postacute providers to prioritizing patient preferences when developing discharge plans and treatment goals.
This week's note from the instructor discusses operational considerations to make while implementing new billing processes for therapy assistant modifiers.
Chimeric antigen receptor T-cell (CAR-T) therapy provided to Medicare Advantage (MA) beneficiaries will be paid for by traditional Medicare for calendar years 2019 and 2020.
This week’s Medicare updates include the October edition of the Medicare Quarterly Compliance Newsletter, a pair of requests for information on potential usage of artificial intelligence to prevent fraud, Medicare Advantage billing instructions for CAR-T therapy, and more!
